Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03842501 · ClinicalTrials.gov registry record · Phase 3
Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity
A Phase 3 study of Obesity, sponsored by Golo.
- Completed
- Registry status
- Phase 3
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT03842501 is a Phase 3 study of Obesity that has completed, run by Golo. The registered enrollment target is 68 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03842501, a Phase 3 study of Obesity, has completed, sponsored by Golo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized, double-blind placebo-controlled study was intended to measure the effects of the GWMP with Release supplement versus GWMP with placebo supplement in a representative group of obese subjects with or without diabetes at one outpatient medical practice.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Release Supplement
Study Locations (1)
Indiana
- Buynak Clinical Research - Valparaiso
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2018-07-01 |
| Est. Completion | 2018-12-24 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03842501
The ClinicalTrials.gov registry entry for NCT03842501 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (92% lower). The listed sponsor is Golo, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03842501 reports 1 study location spanning 1 distinct geographic area - top geographies include Indiana.
Frequently Asked Questions
What is clinical trial NCT03842501 about?
NCT03842501 is a clinical study titled "Effects of the GOLO Weight Management Program With and Without Release Supplement on Weight and Metabolic Parameters in Subjects With Obesity". This randomized, double-blind placebo-controlled study was intended to measure the effects of the GWMP with Release supplement versus GWMP with placebo supplement in a representative group of obese subjects with or without diabetes at one outpatient medical practice.
What is the current status of trial NCT03842501?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 68 participants. The study started on 2018-07-01. Estimated completion is 2018-12-24.
What conditions does trial NCT03842501 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT03842501?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Release Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03842501?
This trial is sponsored by Golo, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03842501 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.